Evidence map›Paper›PMID 38991033›Full record

ArticlePLoS biology2024

Mutations in nucleotide metabolism genes bypass proteasome defects in png-1/NGLY1-deficient Caenorhabditis elegans.

Katherine S Yanagi, Briar Jochim, Sheikh Omar Kunjo, Peter Breen, Gary Ruvkun, Nicolas Lehrbach

Abstract read
In one paragraph

Article in PLoS biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. XDH-1 inactivation causes xanthine stone formation inbioRxiv : the preprint server for biology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katherine S YanagiBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Briar JochimBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Sheikh Omar KunjoBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Peter BreenDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Gary RuvkunDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Nicolas LehrbachBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.ORCID 0000-0001-7342-4136

Funding

GENETIC AND MOLECULAR BASIS OF LONGEVITYR01AG016636 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1999 to 2026
$12.4M
Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Aric L Daul, Ann E. Rougvie · 2012 to 2026
$7.5M
Regulation of Proteasome CapacityR35GM142728 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEHRBACH, NICOLAS JOHN · 2021 to 2025
$2.3M
NIA NIH HHS R01 AG016636NIGMS NIH HHS R35 GM142728NIH HHS P40 OD010440
6 · The paper itself

Abstract

The conserved SKN-1A/Nrf1 transcription factor regulates the expression of proteasome subunit genes and is essential for maintenance of adequate proteasome function in animal development, aging, and stress responses. Unusual among transcription factors, SKN-1A/Nrf1 is a glycoprotein synthesized in the endoplasmic reticulum (ER). N-glycosylated SKN-1A/Nrf1 exits the ER and is deglycosylated in the cytosol by the PNG-1/NGLY1 peptide:N-glycanase. Deglycosylation edits the protein sequence of SKN-1A/Nrf1 by converting N-glycosylated asparagine residues to aspartate, which is necessary for SKN-1A/Nrf1 transcriptional activation of proteasome subunit genes. Homozygous loss-of-function mutations in the peptide:N-glycanase (NGLY1) gene cause NGLY1 deficiency, a congenital disorder of deglycosylation. There are no effective treatments for NGLY1 deficiency. Since SKN-1A/Nrf1 is a major client of NGLY1, the resulting proteasome deficit contributes to NGLY1 disease. We sought to identify targets for mitigation of proteasome dysfunction in NGLY1 deficiency that might indicate new avenues for treatment. We isolated mutations that suppress the sensitivity to proteasome inhibitors caused by inactivation of the NGLY1 ortholog PNG-1 in Caenorhabditis elegans. We identified multiple suppressor mutations affecting 3 conserved genes: rsks-1, tald-1, and ent-4. We show that the suppressors act through a SKN-1/Nrf-independent mechanism and confer proteostasis benefits consistent with amelioration of proteasome dysfunction. ent-4 encodes an intestinal nucleoside/nucleotide transporter, and we show that restriction of nucleotide availability is beneficial, whereas a nucleotide-rich diet exacerbates proteasome dysfunction in PNG-1/NGLY1-deficient C. elegans. Our findings suggest that dietary or pharmacological interventions altering nucleotide availability have the potential to mitigate proteasome insufficiency in NGLY1 deficiency and other diseases associated with proteasome dysfunction.

Indexed as

Caenorhabditis elegansCaenorhabditis elegans ProteinsMutationProteasome Endopeptidase ComplexAnimalsCongenital Disorders of GlycosylationDNA-Binding ProteinsGlycosylationNucleotidesPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseTranscription FactorsCaenorhabditis elegans ProteinsDNA-Binding ProteinsNucleotidesPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseProteasome Endopeptidase Complexskn-1 protein, C elegansTranscription Factors

Identifiers

PMID38991033
PMCPMC11265709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.